These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

813 related items for PubMed ID: 37474112

  • 21. Effects of sodium-glucose cotransporter-2 inhibitors and aldosterone antagonists, in addition to renin-angiotensin system antagonists, on major adverse kidney outcomes in patients with type 2 diabetes and chronic kidney disease: A systematic review and network meta-analysis.
    Yang S, Zhao L, Mi Y, He W.
    Diabetes Obes Metab; 2022 Nov; 24(11):2159-2168. PubMed ID: 35712807
    [Abstract] [Full Text] [Related]

  • 22. Cardiovascular and Renal Outcomes With Sodium-Glucose Cotransporter-2 Inhibitors and Dipeptidyl Peptidase-4 Inhibitors Combination Therapy: A Meta-Analysis of Randomized Cardiovascular Outcome Trials.
    Singh AK, Singh A, Singh R.
    Endocr Pract; 2023 Jul; 29(7):509-516. PubMed ID: 37037286
    [Abstract] [Full Text] [Related]

  • 23. SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials.
    Zelniker TA, Wiviott SD, Raz I, Im K, Goodrich EL, Bonaca MP, Mosenzon O, Kato ET, Cahn A, Furtado RHM, Bhatt DL, Leiter LA, McGuire DK, Wilding JPH, Sabatine MS.
    Lancet; 2019 Jan 05; 393(10166):31-39. PubMed ID: 30424892
    [Abstract] [Full Text] [Related]

  • 24. Cardiovascular and renal efficacy and safety of sodium-glucose cotransporter-2 inhibitors in patients without diabetes: a systematic review and meta-analysis of randomised placebo-controlled trials.
    Tsai WC, Hsu SP, Chiu YL, Yang JY, Pai MF, Ko MJ, Tu YK, Hung KY, Chien KL, Peng YS, Wu HY.
    BMJ Open; 2022 Oct 14; 12(10):e060655. PubMed ID: 36241355
    [Abstract] [Full Text] [Related]

  • 25. Effects of SGLT2 inhibitors on cardiovascular and renal outcomes in type 2 diabetes: A meta-analysis with trial sequential analysis.
    Qiu M, Ding L, Zhou H.
    Medicine (Baltimore); 2021 Mar 12; 100(10):e25121. PubMed ID: 33725910
    [Abstract] [Full Text] [Related]

  • 26. Sodium-Glucose Cotransporter-2 Inhibitors in Heart Failure: A Meta-Analysis of Randomized Clinical Trials.
    Kumar K, Kheiri B, Simpson TF, Osman M, Rahmouni H.
    Am J Med; 2020 Nov 12; 133(11):e625-e630. PubMed ID: 32389659
    [Abstract] [Full Text] [Related]

  • 27. Cardiovascular outcomes associated with SGLT-2 inhibitors versus other glucose-lowering drugs in patients with type 2 diabetes: A real-world systematic review and meta-analysis.
    Li CX, Liang S, Gao L, Liu H.
    PLoS One; 2021 Nov 12; 16(2):e0244689. PubMed ID: 33606705
    [Abstract] [Full Text] [Related]

  • 28. Heart failure hospitalisation relative to major atherosclerotic events in type 2 diabetes with versus without chronic kidney disease: A meta-analysis of cardiovascular outcomes trials.
    Sacre JW, Magliano DJ, Shaw JE.
    Diabetes Metab; 2021 Sep 12; 47(5):101249. PubMed ID: 33744399
    [Abstract] [Full Text] [Related]

  • 29. Association of sodium-glucose cotransporter 2 inhibitors with cardiovascular outcome and safety events: A meta-analysis of randomized controlled clinical trials.
    Gong C, Shen SC, Zhang K, Zhou L, Shen JJ, Zhao JY, Ding SG, Ma LK, Gao H.
    Front Cardiovasc Med; 2022 Sep 12; 9():926979. PubMed ID: 36312269
    [Abstract] [Full Text] [Related]

  • 30. SGLT2 inhibitors in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials balancing their risks and benefits.
    Marilly E, Cottin J, Cabrera N, Cornu C, Boussageon R, Moulin P, Lega JC, Gueyffier F, Cucherat M, Grenet G.
    Diabetologia; 2022 Dec 12; 65(12):2000-2010. PubMed ID: 35925319
    [Abstract] [Full Text] [Related]

  • 31. Effects of the Sodium-Glucose Cotransporter Inhibitors on Cardiovascular Death and All-Cause Mortality: A Systematic Review and Meta-analysis of Randomized Placebo-Controlled Clinical Trials.
    Eraikhuemen N, Leung S, Warren SB, Lazaridis D, Smith CH, Kearson ML, Marcellus V.
    Am J Cardiovasc Drugs; 2023 Mar 12; 23(2):113-126. PubMed ID: 36572841
    [Abstract] [Full Text] [Related]

  • 32. Cardiorenal outcomes with sodium/glucose cotransporter-2 inhibitors in patients with type 2 diabetes and low kidney risk: real world evidence.
    Schechter M, Melzer-Cohen C, Rozenberg A, Yanuv I, Chodick G, Karasik A, Kosiborod M, Mosenzon O.
    Cardiovasc Diabetol; 2021 Aug 18; 20(1):169. PubMed ID: 34407822
    [Abstract] [Full Text] [Related]

  • 33. Effects of SGLT2 inhibitors on cardiovascular, renal, and major safety outcomes in heart failure: A meta-analysis of randomized controlled trials.
    Li X, Zhang Q, Zhu L, Wang G, Ge P, Hu A, Sun X.
    Int J Cardiol; 2021 Jun 01; 332():119-126. PubMed ID: 33838152
    [Abstract] [Full Text] [Related]

  • 34. Comparative Effectiveness of Empagliflozin vs Liraglutide or Sitagliptin in Older Adults With Diverse Patient Characteristics.
    Htoo PT, Tesfaye H, Schneeweiss S, Wexler DJ, Everett BM, Glynn RJ, Kim SC, Najafzadeh M, Koeneman L, Farsani SF, Déruaz-Luyet A, Paik JM, Patorno E.
    JAMA Netw Open; 2022 Oct 03; 5(10):e2237606. PubMed ID: 36264574
    [Abstract] [Full Text] [Related]

  • 35. Incidence of Hospitalization for Heart Failure Relative to Major Atherosclerotic Events in Type 2 Diabetes: A Meta-analysis of Cardiovascular Outcomes Trials.
    Sacre JW, Magliano DJ, Shaw JE.
    Diabetes Care; 2020 Oct 03; 43(10):2614-2623. PubMed ID: 32958618
    [Abstract] [Full Text] [Related]

  • 36. The effect of DPP-4 inhibitors, GLP-1 receptor agonists and SGLT-2 inhibitors on cardiorenal outcomes: a network meta-analysis of 23 CVOTs.
    Giugliano D, Longo M, Signoriello S, Maiorino MI, Solerte B, Chiodini P, Esposito K.
    Cardiovasc Diabetol; 2022 Mar 16; 21(1):42. PubMed ID: 35296336
    [Abstract] [Full Text] [Related]

  • 37. Prevention of heart failure events with sodium-glucose co-transporter 2 inhibitors across a spectrum of cardio-renal-metabolic risk.
    Bhatia K, Jain V, Gupta K, Bansal A, Fox A, Qamar A, Damman K, Vaduganathan M.
    Eur J Heart Fail; 2021 Jun 16; 23(6):1002-1008. PubMed ID: 33609071
    [Abstract] [Full Text] [Related]

  • 38. The cardiovascular effects of SGLT2 inhibitors, RAS inhibitors, and ARN inhibitors in heart failure.
    Ji PJ, Zhang ZY, Yan Q, Cao HL, Zhao YJ, Yang B, Li J.
    ESC Heart Fail; 2023 Apr 16; 10(2):1314-1325. PubMed ID: 36722326
    [Abstract] [Full Text] [Related]

  • 39. Sodium-glucose cotransporter-2 inhibition for heart failure with preserved ejection fraction and chronic kidney disease with or without type 2 diabetes mellitus: a narrative review.
    Mentz RJ, Brunton SA, Rangaswami J.
    Cardiovasc Diabetol; 2023 Nov 16; 22(1):316. PubMed ID: 37974185
    [Abstract] [Full Text] [Related]

  • 40. Cardiovascular outcomes with SGLT2 inhibitors versus DPP4 inhibitors and GLP-1 receptor agonists in patients with heart failure with reduced and preserved ejection fraction.
    Gonzalez J, Bates BA, Setoguchi S, Gerhard T, Dave CV.
    Cardiovasc Diabetol; 2023 Mar 10; 22(1):54. PubMed ID: 36899387
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 41.